Research in the field of haemoglobinopathies, and in particular for sickle cell disease, has enabled the implementation of new therapies, both modifying and curative. The congress was the opportunity to present the experience gained from their use in real life or in phase III trials; it has demonstrated their potential benefit while emphasising that careful monitoring of these new treatments remains necessary. The congress was also an opportunity to present new tools used in the field of haemoglobinopathies. They contribute to the assessment of the impact of new modifying therapies in sickle cell disease, i.e., oxygen gradient ektacytometry, or in the field of diagnosis using artificial intelligence, i.e., SCD silent cerebral infarct and liver iron overload.
(BELG J HEMATOL 2022;13(5):207–9)